Literature DB >> 7535192

Nitroglycerin-induced headache is not dependent on histamine release: support for a direct nociceptive action of nitric oxide.

H K Iversen1, J Olesen.   

Abstract

The molecular mechanisms of migraine pain have not yet been clarified. Monoamine and the peptide neurotransmitters involved in neurogenic inflammation do not cause significant head pain. Our previous studies of glyceryl trinitrate (GTN) and histamine-induced headaches have suggested that nitric oxide (NO) is the causative molecule in migraine pain. We furthermore suggest that substances capable of inducing experimental vascular headache do so via a common mediator which is NO. Finally, it is suggested that drugs exert their antimigraine activity by inhibiting NO or subsequent steps in the cascade of intracellular reactions triggered by NO. These novel observations change current views on vascular headache mechanisms and the importance of NO as an initiator of the migraine attacks dictates new approaches to the pharmacological treatment of migraine and other vascular headaches.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7535192     DOI: 10.1046/j.1468-2982.1994.1406437.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Peter J Goadsby
Journal:  J Headache Pain       Date:  2010-10-27       Impact factor: 7.277

2.  Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine.

Authors:  L H Lassen; L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Indomethacin for refractory COVID or post-COVID headache: a retrospective study.

Authors:  Abouch V Krymchantowski; Raimundo Pereira Silva-Néto; Carla Jevoux; Ana Gabriela Krymchantowski
Journal:  Acta Neurol Belg       Date:  2021-09-21       Impact factor: 2.471

Review 4.  Focus on headache as an adverse reaction to drugs.

Authors:  Anna Ferrari; Luca Spaccapelo; Daniela Gallesi; Emilio Sternieri
Journal:  J Headache Pain       Date:  2009-06-04       Impact factor: 7.277

Review 5.  Human models of migraine - short-term pain for long-term gain.

Authors:  Messoud Ashina; Jakob Møller Hansen; Bára Oladóttir Á Dunga; Jes Olesen
Journal:  Nat Rev Neurol       Date:  2017-10-06       Impact factor: 42.937

6.  Headache as an Adverse Reaction to the Use of Medication in the Elderly: A Pharmacovigilance Study.

Authors:  Cristina Monteiro; Beatriz Dias; Maria Vaz-Patto
Journal:  Int J Environ Res Public Health       Date:  2021-03-07       Impact factor: 3.390

Review 7.  TRPA1 and other TRP channels in migraine.

Authors:  Silvia Benemei; Francesco De Cesaris; Camilla Fusi; Eleonora Rossi; Chiara Lupi; Pierangelo Geppetti
Journal:  J Headache Pain       Date:  2013-08-13       Impact factor: 7.277

8.  Differential actions of indomethacin: clinical relevance in headache.

Authors:  Oliver Summ; Anna P Andreou; Simon Akerman; Philip R Holland; Jan Hoffmann; Peter J Goadsby
Journal:  Pain       Date:  2021-02-01       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.